Norton CFC-free beclomethasone inhaler U.K. approval could come this year following patent victory.
NORTON ANTICIPATES CFC-FREE BECLOMETHASONE INHALER U.K. APPROVAL IN LATE 1997 following a recent victory over 3M in the British patent courts. The U.K. court invalidated three European patents held by 3M which relate to the use of the CFC-free propellant P134a in metered dose inhalers. The ruling clears the way for Ivax' U.K. subsidiary Norton Healthcare to market its CFC-free beclomethasone inhaler in Great Britain once the product is approved by the Medicines Control Agency. Norton is predicting a U.K. launch in early 1998.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth